Loading stock data…
SMMT
$16.11-5.34 (-24.91%)
Market ClosedLast close May 1
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Summit Therapeutics Inc. in the Healthcare sector is trading at $16.11. The stock is currently near its 52-week low of $13.83, remaining 18.2% below its 200-day moving average. Technical signals show neutral RSI of 39 and bearish MACD signal, explaining why SMMT maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 39) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$16.11
Potential Upside
5%
Whystock Fair Value$16.92
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Buy
Mean target$31.10+93.0%
Range$12.06 – $45.22
Fundamentals
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$17.28B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.37
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-113.24%
Volume
Today's trading volume
18.00M
Recent News
Merck's Biggest Looming Rival In Cancer Just Took A Gut Punch
Summit Therapeutics stock crashed Friday after the company said its lung cancer treatment didn't pass muster at an interim analysis.
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast cancer medicine.
SMMT Stock Up 24% in Three Months: Here's What You Need to Know
Summit Therapeutics stock jumps as FDA accepts ivonescimab BLA. Strong trial data and partnerships boost confidence in its cancer therapy pipeline.
A Look At Summit Therapeutics (SMMT) Valuation After New Ivonescimab Phase III Data And FDA BLA Filing
Summit Therapeutics (SMMT) drew fresh attention after presenting new Phase III ivonescimab data at the 2026 European Lung Cancer Congress, alongside an FDA Biologics License Application filing for EGFR-mutated NSCLC treatment. See our latest analysis for Summit Therapeutics. The latest ivonescimab data and BLA filing arrive after a mixed price pattern, with a 6.9% 7 day share price return and a 5.7% 30 day gain, yet a 1 year total shareholder return decline of 18.4% set against a very large 3...
Summit Therapeutics (SMMT) Is Up 6.9% After Phase III Ivonescimab Data And FDA Filing - What's Changed
Summit Therapeutics recently presented Phase III data for its investigational bispecific antibody ivonescimab at the European Lung Cancer Congress in Copenhagen, showing improved intracranial progression-free survival in EGFR‑mutated non-small cell lung cancer and confirming that a Biologics License Application has been submitted to the FDA. The breadth of the ivonescimab program, spanning 15 Phase III studies across lung and colorectal cancer and involving global and China-based trials with...